source
- Genmab’s Rina-S ADC cuts risk of progression and death in Phase 3 ovarian cancer trialGenmab reported results from its Phase 3 RAINFOL-02 trial of the FRα‑directed antibody‑drug conjugate Rina‑S (rinatabart sesutecan) in patients with platinum‑resistant ovarian cancer. In the inten…
- Biotech IPOs Pull in $7.5B Across 22 Deals in 2026, While Market Gains Stall in Q3Biopharma companies raised about $7.5 billion from 22 initial public offerings in the first three quarters of 2026, according to J.P. Morgan data. This level of financing far exceeds the eight offe…